NYSE · Medical - Diagnostics & Research
RVTY (RVTY) Stock
$115.02
+3.26%
NYSE: RVTY
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Revvity to Launch Signals for Startups for Emerging Biotech Companies
Zacks · Jul 22, 2026
Revvity Launches "Signals for Startups" to Help Emerging Biotechs Build Scalable Digital Foundations from Day One
Business Wire · Jul 20, 2026
Revvity Releases 2026 Impact Report Advancing Transparency with Initial Scope 3 Emissions Disclosure
Business Wire · Jul 20, 2026
TD Cowen Adjusts Price Target on Revvity to $130 From $120, Maintains Buy Rating
MT Newswires · Jul 15, 2026
Alamar Hits A High Note On Alzheimer's Buzz
Trefis · Jul 13, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held0.35%
Institutions Held106.37%
Institutions Float Held106.75%
Peer Comparison
About RVTY
RVTY is led by CEO Prahlad R. Singh, employs 11,000 people, headquartered in Waltham, US, publicly traded since 1965.
RVTY stock trades at $115.02 with a market capitalization of $12.83B. The stock is valued at a price-to-earnings (P/E) ratio of 46.33, price-to-book of 1.48, price-to-sales of 3.68. Over the past 52 weeks the stock has ranged between $81.22 and $118.30, and currently trades 2.8% below its 52-week high. It pays a dividend yielding 0.29%.
On profitability, RVTY generates a return on equity (ROE) of 3.34%, return on capital employed of 4.92%, an operating margin of 12.50%, a net profit margin of 8.30%.